Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy Vaccines
Johns Hopkins University details research in cancer gene therapy vaccines
September 3rd, 2008
A report, 'Current status of experimental therapeutics for prostate cancer,' is newly published data in Cancer Letters. "Hormone refractory prostate cancer (HRPC) is the progression of disease in the presence of castrate serum levels of testosterone with a median survival of approximately 1 year. A variety of strategies have been developed to improve survival for the patients with advanced prostate cancer," researchers in the United States report. "Despite such efforts, the effective treatment modality for those patients has not been established other than chemotherapy. New experimental therapeutics such as gene therapy, vaccine therapy and target therapy use...
Source: Vaccine Weekly (2008-09-03)
|
